About Yehuda Handelsman, MD, FACP, FACE, FNLA
Dr. Yehuda Handelsman is the medical director and principal investigator of the Metabolic Institute of America and an endocrinologist in solo private practice in Tarzana, California, where he developed and successfully utilizes a comprehensive and unique, multiple interventional approaches to the cardio-metabolic high risk patient, preventing and managing obesity, diabetes, and cardiovascular disease. He has been listed repeatedly in “Top Doctors of Los Angeles”, “Southern California Super Doctors” and “Best Doctors of America”.
Dr. Handelsman is president of the American College of Endocrinology, a past President of the American Association of Clinical Endocrinologists, and the secretary of the Pacific Lipid Association. He is chair & program director of the annual World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease, chair of the international committee for insulin resistance and senior scientific consultant for the Metabolic Endocrine Education Foundation. He has published extensively, researched, and is a frequent lecturer on diabetes and its comprehensive treatment, focusing on comprehensive approaches to managing diabetes-controlling obesity, HTN, lipids and the prevention of kidney disease, and cardiovascular disease. Handelsman has also been a national and international consultant and recognized expert on insulin resistance, metabolic syndromes, pre-diabetes, incretins and gut hormones, the gut brain connection, multi-hormonal obesity and diabetes and cancer. He has also consulted and lectured on lipodystrophy, thyroid and osteoporosis.
Handelsman is an associate editor of the Journal of Diabetes. He frequently serves as guest editor for multiple publications, recently for the Journal of Clinical Hypertension (JCH), Metabolic Syndrome and Related Disorders, and Postgraduate Medicine. He is an editorial board member of Clinical Endocrine News, a member of the editorial panel for the European Medical Journal-Diabetes and a member of the editorial advisory panel of Treatment Strategies-Diabetes at the Cambridge Research Center, United Kingdom.
He is the chair of the American Association of Clinical Endocrinologists (AACE) Diabetes and Lipids Scientific Committees, chair of the AACE/ACE (American College of Endocrinology) 2011 Comprehensive Diabetes Guidelines, chair of the 2014 DM Guideline update committee, and a member of the AACE 2013 Comprehensive Diabetes Algorithm and the 2012 AACE lipid guidelines. He has been chair, member, co-author, and reviewer of many AACE/ACE national guidelines, algorithms, and position statements on obesity, pre-diabetes, diabetes, diabetes & cancer, lipids, and hypertension. Dr. Handelsman is a member of the American College of Endocrinology, American Diabetes Association, National Osteoporosis Foundation, American Thyroid Association, Academy of Thyroidologists, American College of Physicians, Los Angeles & California Medical Associations, and the American Medical Association, as well as the National Lipid Association.
Dr. Handelsman is a Summa Cum Laude graduate of the University of the Pacific, in Stockton, California. He is a Fellow of the American College of Endocrinology, the American College of Physicians, and the National Lipid Association. Dr. Handelsman earned his doctor of medicine degree from Tel Aviv University Sackler Faculty of Medicine in Israel. He completed a subsequent internship and residency in internal medicine at New York Infirmary Beekman Downtown Hospital under the supervision of New York University. His fellowship in diabetes and endocrinology was conducted at the University of Southern California Medical School in Los Angeles.